LOS ANGELES, Sept. 27, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) disclose an opportunity for investors to play a pivotal role in the securities fraud class action lawsuit swirling around Outset Medical, Inc. (“Outset Medical” or the “Company”) OM.

Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024

Should you aspire to spearhead the Outset Medical lawsuit as a lead plaintiff, you can provide your contact details at www.glancylaw.com/cases/Outset-Medical-Inc-1/. For more insights into your rights, get in touch with Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com.

The lawsuit alleges that during the Class Period, Outset Medical concealed critical information from investors. These include misleading marketing of Tablo products for continuous renal replacement therapy, the absence of FDA approval for such indications, potential delays due to pending regulatory approvals, and a deficiency in sales strategies.

Stay updated with us on LinkedIn, Twitter, or Facebook.

To participate in the class action, no immediate action is required; you can retain your own counsel or choose to remain silent as an absent member. For further details on the class action or any inquiries, reach out to Charles Linehan, Esquire, of GPM. Contact details can be found at the bottom of our website.

This announcement may be deemed as Attorney Advertising in specific jurisdictions based on applicable laws and ethical guidelines.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/om-investors-have-opportunity-to-lead-outset-medical-inc-securities-fraud-lawsuit-302261382.html

SOURCE Glancy Prongay & Murray LLP